| For: | Fouad Y. Metabolic-associated fatty liver disease: New nomenclature and approach with hot debate. World J Hepatol 2023; 15(2): 123-128 [PMID: 36926229 DOI: 10.4254/wjh.v15.i2.123] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v15/i2/123.htm |
| Number | Citing Articles |
| 1 |
Wei Zhu, Eleonora Cremonini, Angela Mastaloudis, Patricia I. Oteiza. Glucoraphanin and sulforaphane mitigate TNFα-induced Caco-2 monolayers permeabilization and inflammation. Redox Biology 2024; 76 doi: 10.1016/j.redox.2024.103359
|
| 2 |
Yurina Akeno, Megumi Maeda, Fumiko Murata, Haruhisa Fukuda. Metabolic dysfunction‐associated fatty liver disease and risks of incident coronary artery disease and cerebrovascular disease: LIFE Study. Hepatology Research 2025; 55(6) doi: 10.1111/hepr.14185
|
| 3 |
Yasser Fouad, Mohamed Alboraie, Gamal Shiha. Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease. Hepatology International 2024; 18(S2) doi: 10.1007/s12072-024-10704-3
|
| 4 |
Joshua Kock-Sierra, Juan Felipe Betancur-Pulgarín, Jhon Edwar Bolaños-López, Luz Eugenia Pérez-Jaramillo, Carlos José Bello-Gándara, Farley Johanna González-Patiño, José David Sanabria-Vanegas, José David Manga-Peña, Carlos Andrés Badillo-Blanco. Caracterización de la enfermedad hepática crónica, cirrosis y progresión a carcinoma hepatocelular en una entidad promotora de salud en Colombia: estudio retrospectivo de diez años. Hepatología 2025; 6(2) doi: 10.59093/27112330.134
|
| 5 |
Alaa M. Mostafa, Yasser Fouad, Ziayn Pan, Shereen Abdel Alem, Mohamed AbdAllah, Eman Abdelsameea, Mohammed Eslam. MAFLD increases CKM syndrome severity: a NHANES-based cross-sectional study. Clinical and Experimental Medicine 2025; 26(1) doi: 10.1007/s10238-025-01997-1
|
| 6 |
José González Fernández, Lucía Prieto-Torres, Mariano Ara Martín, Samuel J. Martínez-Domínguez. MASLD and liver fibrosis in patients with psoriasis receiving IL-17 or IL-23 inhibitors: a systematic review. Therapeutic Advances in Gastroenterology 2025; 18 doi: 10.1177/17562848251335824
|
| 7 |
Anil C. Anand. MASLD, MLA Pesarattu and Other Developments. Journal of Clinical and Experimental Hepatology 2025; 15(1) doi: 10.1016/j.jceh.2024.102465
|
| 8 |
Nso Nso, Damla Mergen, Mashaal Ikram, Victor Macrinici, Kifah Hussain, Kevin Lee, Derek Ugwendum, Mia Trimingham, Senthil Balasubramanian, Riya Sam, Basile Njei. Cardiovascular morbidity and mortality in lean vs. non-lean MASLD: A comprehensive meta-analysis. Current Problems in Cardiology 2024; 49(6) doi: 10.1016/j.cpcardiol.2024.102569
|
| 9 |
Abhay Sahoo, Balram Sharma, Himanshu Patil, M. R. Warun Kumar, Nilakshi Deka, Piyush Lodha, Sailesh Lodha, Sajal Kamat, Sreedevi Patnala, Sujit Chandratraya, Vinayak Harale, Hiren Prajapati, Disha Shah. Disease-modifying combination of Dapagliflozin plus Pioglitazone in the Management of Metabolic Dysfunction-associated Fatty Liver Disease in Type 2 Diabetes. International Journal of Diabetes and Technology 2025; 4(4) doi: 10.4103/ijdt.ijdt_26_25
|
| 10 |
Joseph A. M. J. L. Janssen. Overnutrition, Hyperinsulinemia and Ectopic Fat: It Is Time for A Paradigm Shift in the Management of Type 2 Diabetes. International Journal of Molecular Sciences 2024; 25(10) doi: 10.3390/ijms25105488
|
| 11 |
Yazhi Wang, Mingkang Zhang, Peng Wang. Associations Between Novel Lipid Indicators and the Risk of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes. Lipids 2025; 60(6) doi: 10.1002/lipd.12453
|
| 12 |
Perry J. Pickhardt, Glen M. Blake, Yotam Kimmel, Esther Weinstock, Keren Shaanan, Shiri Hassid, Ahmad Abbas, Matthew A. Fox. Detection of Moderate Hepatic Steatosis on Portal Venous Phase Contrast-Enhanced CT: Evaluation Using an Automated Artificial Intelligence Tool. American Journal of Roentgenology 2023; 221(6) doi: 10.2214/AJR.23.29651
|
| 13 |
Damian Dyńka, Łukasz Rodzeń, Mateusz Rodzeń, Dorota Łojko, Sebastian Kraszewski, Ali Ibrahim, Maria Hussey, Adam Deptuła, Żaneta Grzywacz, Alexandre Ternianov, David Unwin. Beneficial Effects of the Ketogenic Diet on Nonalcoholic Fatty Liver Disease (NAFLD/MAFLD). Journal of Clinical Medicine 2024; 13(16) doi: 10.3390/jcm13164857
|
| 14 |
Saima Ajaz, Mark Chamley, James Lok, Riham Soliman, Reece Khan, Karan Ahir, Monique Curtis, María Fernanda Guerra-Veloz, Kosh Agarwal. Lack of awareness and ethnic polarity is a major cause of metabolic associated fatty liver disease in high-risk diabetes population in South London. Therapeutic Advances in Chronic Disease 2024; 15 doi: 10.1177/20406223241264539
|
| 15 |
Yuan Yao, Yunfeng Shen. Cross-talk between gut microbiota and liver steatosis: Complications and therapeutic target. Open Life Sciences 2023; 18(1) doi: 10.1515/biol-2022-0699
|
| 16 |
Yasser Fouad, Amr Abdel Zaher Shehata. When the liver hardens the heart: Valvular calcification as an emerging cardiohepatic phenotype in cirrhosis. World Journal of Cardiology 2026; 18(5): 119394 doi: 10.4330/wjc.v18.i5.119394
|
| 17 |
Ji Lee, Sue Kim, Yaeji Lee, Yu-Jin Kwon, Ji-Won Lee. Higher Adherence to the Mediterranean Diet Is Associated with a Lower Risk of Steatotic, Alcohol-Related, and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Analysis. Nutrients 2024; 16(20) doi: 10.3390/nu16203551
|
| 18 |
Ruth Tulleners, Adrian Barnett, James O'Beirne, Elizabeth Powell, Ingrid J Hickman, Patricia C Valery, Sanjeewa Kularatna, Katherine Stuart, Carolyn McIvor, Elen Witness, Melanie Aikebuse, David Brain. Parallel randomised trial testing community fibrosis assessment for suspected non-alcoholic fatty liver disease: outcomes from LOCATE-NAFLD. BMJ Open Gastroenterology 2024; 11(1) doi: 10.1136/bmjgast-2024-001418
|
| 19 |
Giulia de Alteriis, Gabriella Pugliese, Antonella Di Sarno, Giovanna Muscogiuri, Luigi Barrea, Valentina Cossiga, Giuseppe Perruolo, Michele Francesco Di Tolla, Francesca Zumbolo, Pietro Formisano, Filomena Morisco, Silvia Savastano. Visceral Obesity and Cytokeratin-18 Antigens as Early Biomarkers of Liver Damage. International Journal of Molecular Sciences 2023; 24(13) doi: 10.3390/ijms241310885
|
| 20 |
Borong Yu, Yuhe Liu, Wenqian Wu, Yong Zhou, Dan Han, Yuanwen Chen. Association of Hyperbilirubinemia with Lipid Profile and Lipid-Related Diseases: A Large Community-Based Cohort Study. Journal of Clinical Medicine 2026; 15(2) doi: 10.3390/jcm15020455
|
| 21 |
Yasser Fouad, Faisal Sanai, Mohamed Alboraie, Ming-Hua Zheng. What the New Definition of MASLD Left Behind: Dual Etiology With Viral Hepatitis. Clinical Gastroenterology and Hepatology 2024; 22(8) doi: 10.1016/j.cgh.2023.11.026
|
| 22 |
Yang Zhang, Qiangman Wei, Xue Geng, Guoliang Fang. Long-Term Aerobic Exercise Enhances Hepatoprotection in MAFLD by Modulating Exosomal miR-324 via ROCK1. Metabolites 2024; 14(12) doi: 10.3390/metabo14120692
|
| 23 |
Nicolás Jesús Garrido, Miguel Suárez, Jorge Mateo. Steatotic liver disease in people with human immunodeficiency virus: A narrative review of metabolic steatotic liver disorders. World Journal of Hepatology 2026; 18(5): 117567 doi: 10.4254/wjh.v18.i5.117567
|
| 24 |
Consolato M. Sergi. NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review. International Journal of Molecular Sciences 2024; 25(15) doi: 10.3390/ijms25158462
|
| 25 |
O.M. Radchenko, O.J. Komarytsia, M.O. Borovets, R.S. Ivasivka, R.R. Guta. Proinflammatory interleukins 2, 6 and tumor necrosis factor alpha in patients with hypertension and diabetes mellitus depending on the presence of metabolic-associated liver steatosis. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) 2024; 20(3) doi: 10.22141/2224-0721.20.3.2024.1389
|
| 26 |
Anil Chandra Anand, Dibyalochan Praharaj. MASLD or MAFLD: fatty liver by any name will pose the same challenge. Metabolism and Target Organ Damage 2025; 5(2) doi: 10.20517/mtod.2025.18
|
| 27 |
Mohammad Habibullah, Khaleed Jemmieh, Amr Ouda, Mohammad Zulqurnain Haider, Mohammed Imad Malki, Abdel-Naser Elzouki. Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies. Frontiers in Medicine 2024; 11 doi: 10.3389/fmed.2024.1291501
|